Kelonia
keloniatx.com
Actively hiring
Health Care
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$50M
1 round on record
Latest round
$50M
Venture round · May 2022 · 4 yr ago
Backers
1
Alta Partners
The money's age
Long since its last round
52 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 22, 2022
Raised a round Venture round $50M · MedCity News
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | May 2022 | $50M | — | MedCity News |
Backed byfrom the funds' portfolios and accelerator catalogs
Alta Partners Investors in similar startupsfunds that back the companies most like this one
backs Nanograb
backs Transcarent
Similar startupsby what they do, their industry and backers
Nanograb is building the future of AI-powered targeted gene delivery.
Protein Splicing to Develop the Next Generation of Genetic Medicines.
OPT/NET B.V. builds comprehensive Mission Critical AI products for data-driven environments based on decades of hardcore critical industry…
Atsena is a clinical-stage gene therapy company, focused on bringing the life-changing power of genetic medicine to reverse or prevent…
LUUM Lash is revolutionizing the beauty industry with the world.
ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our…
Overview
Kelonia is revolutionizing gene delivery to expand the impact of genetic medicines; built on decades of research, development, and technical experience.
News
LLY to Buy Oncology Biotech Kelonia Therapeutics for $7 Billion
Eli Lilly is set to acquire Kelonia Therapeutics in a $7B deal, boosting its genetic medicine platform with a novel in vivo CAR-T therapy for cancer.
Read more
Report
Eli Lilly Buys Kelonia Therapeutics for $7 Billion to Boost Cancer Treatment Pipeline
It's the second major acquisition in less than a month for Eli Lilly.
Read more
Report
Eli Lilly and Co to Acquire Kelonia Therapeutics, Company Announces
Eli Lilly announced a deal to acquire Kelonia Therapeutics, aiming to expand its cancer treatment portfolio with next-generation therapies.
Read more
Report
Report
Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says
April 19 (Reuters) - U.S. drugmaker Eli Lilly is in advanced talks to acquire biotech firm Kelonia Therapeutics for more than $2 billion, the Wall Street Journal reported on Sunday.
Read more
Report
Kelonia's in vivo CAR-T data will feature at ASH
Kelonia only started human testing of its in vivo CAR-T therapy for multiple myeloma in August, but will report impressive results at ASH next month
Read more
Report
Astellas teams up with startup Kelonia to make 'in vivo' cell therapies
Kelonia will receive $40 million upfront through thepartnership, and could receive $35 million more if Astellas opts into another program.
Read more
Report
CAR T without the toxicity: Kelonia gets $50M for a new take on cell therapy
Kelonia Therapeutics is developing cell therapies made by the in vivo engineering of a patient's cells made possible by the targeted delivery of a genetic payload. The startup, newly out of stealth with $50M in funding, claims its approach would offer man
Read more
Report
Financials
Total raised
$50M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2022 | $50M | Details |